DIVI S LABORATORIES LTD vs GLENMARK PHARMACEUTICALS
A side-by-side comparison of DIVI S LABORATORIES LTD (DIVISLAB) and GLENMARK PHARMACEUTICALS (GLENMARK) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
DIVI S LABORATORIES LTD vs GLENMARK PHARMACEUTICALS are evenly matched on the numbers (7–7). The breakdown below shows where each one wins.
- Valuation22
- Profitability22
- Growth02
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
GLENMARK takes 2/2Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
DIVISLAB takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 39.0%"]
- − ["Stock is trading at 14.6 times its book value", "The company has delivered a poor sales growth of 8.67% over past five years."]
- + ["Company has reduced debt.", "Company is almost debt free.", "Company has delivered good profit growth of 19.4% CAGR over last 5 years"]
- − ["The company has delivered a poor sales growth of 9.19% over past five years.", "Company has a low return on equity of -3.28% over last 3 years.", "Debtor days have increased from 85.2 to 107 days.", "Working capital days have increased from 41.2 days to 80.5 days"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.